Cadila Pharmaceuticals: Difference between revisions

What links here Related changes Page information Get shortened URL
Created by Asinolii
Last edited October 14, 2025
← Older edit
VisualWikitext
imported>Rsrikanth05
No edit summary
m Updated article with clearer structure
 
Line 1: Line 1:
{{Short description|Indian pharmaceutical company}}
{{Use dmy dates|date=August 2018}}
{{Use dmy dates|date=August 2018}}
{{Use Indian English|date=August 2018}}
{{Use Indian English|date=August 2018}}
:''Not to be confused with [[Cadila Healthcare]]''
{{Infobox company
{{Infobox company
| name = Cadila Pharmaceuticals Limited
| name = Cadila Pharmaceuticals Limited
| logo = Cadila Pharmaceuticals Logo.jpg
| logo = Cadila Pharmaceuticals.svg
| logo_size = 220px
| logo_size = 220px
| logo_alt = Cadila_Pharmaceuticals_Logo
| logo_alt = Cadila_Pharmaceuticals_Logo
| image =  
| image = Cadilla Pharmaceuticals HQ.jpg
| type = Private company
| image_size = 250px
| image_caption = Headquarters in [[Ahmedabad]]
| type = [[Private company|Private]]
| foundation = 1951
| foundation = 1951
| founder = [[Indravadan Modi]]
| founder = [[Indravadan Modi]]
| location_city = [[Ahmedabad]], [[Gujarat]]
| location_city = [[Ahmedabad]], [[Gujarat]]
| num_employees = 8000
| num_employees = 8,000
| subsid = IRM Ltd
| subsid = IRM Ltd
| location_country = India
| location_country = India
| key_people = Dr. Rajiv Modi <br />(Chairman and Managing Director)
| key_people = Rajiv Modi <br />(Chairman and Managing Director)
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| products = [[API]]s, [[Generic drug]]s
| products = [[Active ingredient|API]]s, [[generic drug]]s
| services = Contract Research, [[Contract Manufacturing]]
| services = {{ubl|[[Contract research organization|Contract research]]|[[Contract manufacturing]]}}
| revenue = {{up}} {{INRConvert|3675|c}} (FY23)<ref name="FY23"/>
| net_income = {{down}} {{INRConvert|-10|c}} (FY23)<ref name="FY23">{{cite web |title=Cadila Pharmaceuticals Limited |url=https://www.crediwatch.com/party/55675e4e6d6f6f263ac91704/financials |publisher=Crediwatch |access-date=18 December 2023|url-access=registration}}</ref>
| homepage = {{URL|http://www.cadilapharma.com/}}
| homepage = {{URL|http://www.cadilapharma.com/}}
}}
}}


'''Cadila Pharmaceuticals''' is an Indian [[multinational corporation|multinational]] pharmaceutical group based in [[Ahmedabad]], [[Gujarat]], India. With more than 6 decades of experience, the company's integrated operations focus on manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by International bodies such as WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. The company's international operation of is spread across 58 countries including the Americas, Japan, Asia, CIS and Africa.<ref>{{cite web|url=https://www.cphi.com/europe/exhibitors/cadila-pharmaceuticals-ltd|title=Cadila Pharmaceuticals Ltd|date=13 September 2018|website=CPhI Worldwide - Uniting the Pharmaceutical Industry}}</ref>
'''Cadila Pharmaceuticals''' is an Indian [[multinational corporation|multinational]] pharmaceutical company based in [[Ahmedabad]]. The company's operations focus on manufacturing products ranging from [[Active ingredient|active pharmaceutical intermediates]], [[Pharmaceutical formulation|finished formulations]], food supplements, [[biotechnology]] products and pharmaceutical machinery.<ref name="Bureau 2023 v619">{{cite web |last= |first= |date=2023-03-22 |title=Cadila Pharma to expand and upgrade its existing facilities in Gujarat |url=https://www.thehindubusinessline.com/companies/cadila-pharma-to-expand-and-upgrade-its-existing-facilities-in-gujarat/article66649134.ece |access-date=2023-09-11 |website=BusinessLine}}</ref>


== History  ==
== History  ==
[[File:Indravadan A Modi.jpg|right|thumb|300px|Indravadan Modi, Founder]]
In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation.<ref name="auto">{{cite web|url=https://www.business-standard.com/article/companies/carrying-the-legacy-forward-rajiv-modi-114012801184_1.html|title=Carrying the legacy forward: Rajiv Modi|first=Sohini|last=Das|date=28 January 2014|publisher=|via=Business Standard}}</ref>
===Cadila Laboratories ===
In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company that started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation had come a long way.<ref name="auto">{{cite web|url=https://www.business-standard.com/article/companies/carrying-the-legacy-forward-rajiv-modi-114012801184_1.html|title=Carrying the legacy forward: Rajiv Modi|first=Sohini|last=Das|date=28 January 2014|publisher=|via=Business Standard}}</ref>


=== 1995: Birth of Cadila Pharmaceuticals ===
The Modi and Patel families decided to split the business in 1995, and two entities were formed: '''Cadila Pharmaceuticals Ltd''' (owned and controlled by Indravadan Modi and his son Rajiv Modi) and [[Cadila Healthcare]] (owned by Ramanbhai Patel and his son Pankaj Patel family).<ref name="auto"/>
The Modi and Patel families decided to split the business in 1995, two entities were formed - '''Cadila Pharmaceuticals Ltd''' (owned and controlled by Shri. I A Modi and his son Dr. Rajiv Modi) and [[Cadila Healthcare]] (owned by Shri. Ramanbhai Patel and his son Pankaj Patel family). Rajiv Modi and I A Modi worked closely to run Cadila Pharma, now considered one of the largest privately-held pharma companies in the country.<ref name="auto"/>
 
In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals  to develop new treatment for heart patients.<ref>{{Cite web|url=https://www.thehindubusinessline.com/companies/cadila-pharma-inks-pact-with-norwegian-start-up-to-develop-new-treatment-for-heart-patients/article25960391.ece|title=Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients|website=@businessline|date=10 January 2019 |language=en|access-date=2019-01-11}}</ref>
 
In November 2023, the company opened an active pharmaceutical ingredient (API) plant in [[Dahej]], in Gujarat's [[Bharuch district]]. The facility was built with an investment of ₹200 crore, and is equipped with distributed control system (DCS) automation technology. <ref>{{Cite web |title=Business today |date=27 November 2023 |url=https://www.businesstoday.in/industry/pharma/story/cadila-pharmaceuticals-inaugurates-rs-200-crore-api-plant-in-dahej-aims-to-expand-to-new-markets-407301-2023-11-27}}</ref>


== Operations  ==
== Operations  ==
Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and  2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.<ref>[http://pharma.financialexpress.com/sections/management/1698-caring-cadila Financial Express 28 January 2013]</ref>
Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and  2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.<ref>[http://pharma.financialexpress.com/sections/management/1698-caring-cadila Financial Express 28 January 2013]</ref>


== Research ==
== Controversies ==
Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists.
 
The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.<ref>{{cite web|url=http://www.indiainbusiness.nic.in/economy/pharma.htm|title=Welcome to India in Business|website=www.indiainbusiness.nic.in|access-date=24 March 2014|archive-url=https://web.archive.org/web/20140707164613/http://www.indiainbusiness.nic.in/economy/pharma.htm|archive-date=7 July 2014|url-status=dead}}</ref>
Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.<ref>{{cite web|url=http://cadilapharma.com/index.php/about-us/milestones/|title=Cadila Pharma|publisher=|access-date=24 March 2014|archive-url=https://web.archive.org/web/20140421143024/http://cadilapharma.com/index.php/about-us/milestones/|archive-date=21 April 2014|url-status=dead}}</ref>
 
== Products and services ==
Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’.<ref>{{cite web|url=https://www.business-standard.com/article/companies/cadila-pharma-unveils-acidity-drug-in-iv-form-104071601136_1.html|title=Cadila Pharma unveils acidity drug in IV form|first=Our Regional|last=Bureau|date=16 July 2004|publisher=|via=Business Standard}}</ref> In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’<ref>{{cite web|url=https://www.dnaindia.com/business/report-cadila-launches-new-drug-for-tb-treatment-1305424|title=Cadila launches new drug for TB treatment|date=31 October 2009|website=dna}}</ref> and world's first drug combination for prevention of Cardiovascular Diseases – ‘[http://polycap.org/ Polycap]’ were introduced by Cadila Pharmaceuticals.<ref>{{cite web|url=https://www.financialexpress.com/archive/cadila-pharmaceuticals-launches-polycap-which-reduces-cardiovascular-and-stroke-risk-substantially/442271/|title=Cadila Pharmaceuticals launches Polycap, which reduces cardiovascular and stroke risk substantially|date=2 April 2009|website=The Financial Express}}</ref>
For the patients suffering from Non Small Cell Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin.<ref>{{cite web|url=http://articles.economictimes.indiatimes.com/2013-11-21/news/44327154_1_nsclc-small-cell-lung-cancer-drug-controller-general|title=Economic Times 21 November 2013|publisher=}}</ref>
Some of the top brands of the company are Aciloc,  Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and [[Sepsivac]].
 
== Alliances ==
In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals  to develop new treatment for heart patients.<ref>{{Cite web|url=https://www.thehindubusinessline.com/companies/cadila-pharma-inks-pact-with-norwegian-start-up-to-develop-new-treatment-for-heart-patients/article25960391.ece|title=Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients|last=Bureau|first=Our|website=@businessline|language=en|access-date=2019-01-11}}</ref>


== Awards and Recognition ==
=== Company ===
Most Trusted Companies of 2008, Sara Media and Zee Business<ref>{{Cite web|url=https://www.deshgujarat.com/2012/11/26/indravadan-a-modi-the-medicine-man-of-india/|title=Indravadan A Modi: The medicine man of India|date=2012-11-26|website=DeshGujarat|language=en-US|access-date=2019-10-16}}</ref>
In 2014, a cautionary notice appeared on the US [[Food and Drug Administration]] (FDA) website, highlighting substantial manufacturing practice discrepancies discovered by inspectors in March at Cadila Pharmaceuticals' [[Ankleshwar]] facility in Gujarat.<ref>{{Cite news |last1=Mishra |first1=Digbijay |last2=Das |first2=Sohini |date=13 November 2014 |title=US FDA scolds Cadila Pharma over manufacturing practice in Gujrat plant |url=https://www.business-standard.com/article/companies/us-fda-scolds-cadila-pharma-over-manufacturing-practice-in-gujrat-plant-114111201228_1.html |access-date=6 January 2024}}</ref> This incident marked one among several Indian pharmaceutical companies receiving regulatory warnings from the FDA, indicating increased scrutiny on generic drugmakers.<ref>{{Cite news |date=12 November 2014 |title=FDA warns Cadila Pharma over drug production processes |url=https://www.reuters.com/article/cadila-pharmaceuticals-india-usa/fda-warns-cadila-pharma-over-drug-production-processes-idINKCN0IW0EH20141112/ |access-date=6 January 2023 |work=[[Reuters]]}}</ref> A similar kind of notices were again issued in 2016<ref>{{Cite news |last=RAJAGOPAL |first=DIVYA |date=2016-01-01 |title=Cadila gets US FDA warning for violating standards at Moraiya and Ahmedabad plants |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cadila-gets-us-fda-warning-for-violating-standards-at-moraiya-and-ahmedabad-plants/articleshow/50390452.cms |access-date=2024-01-06 |work=The Economic Times |issn=0013-0389}}</ref> and 2019.<ref>{{Cite web |last=Research |first=Center for Drug Evaluation and |date=2022-11-28 |title=Cadila Healthcare Limited - 584856 - 10/29/2019 |url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cadila-healthcare-limited-584856-10292019 |access-date=2024-01-06 |website=Center for Drug Evaluation and Research |language=en}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref>


WorldStar Packaging Award, 2018<ref>{{Cite web|url=https://www.worldstar.org/winner/2019/calcirol-softgel-cadila-pharmaceuticals-limited|title=Calcirol Softgel {{!}} Worldstar|website=www.worldstar.org|access-date=2019-10-16}}</ref>
=== Management ===
 
In 2018, the chairman of the company, Rajiv Modi, went through a widely publicized and contentious divorce with his wife, Monica, who comes from a prominent Mumbai-based business family of Garware. At that time, Modi transferred {{INRConvert|200|c|lk=off|year=2023}} to Monica, who relinquished her rights, while custody of their son was awarded to Modi.<ref>{{Cite news |date=2018-10-31 |title=Gujarat: Cadila Pharma owner pays wife Rs 200 crore |url=https://timesofindia.indiatimes.com/city/ahmedabad/cadila-pharma-owner-pays-wife-rs-200-crore/articleshow/66436382.cms |access-date=2024-01-06 |work=The Times of India |issn=0971-8257}}</ref><ref>{{Cite web |title=Cadila Pharmaceuticals boss Rajiv Modi swallows a Rs 200-cr divorce pill |url=https://www.dnaindia.com/business/report-cadila-pharmaceuticals-boss-rajiv-modi-swallows-a-rs-200-cr-divorce-pill-2681136 |access-date=2024-01-06 |website=DNA India |language=en}}</ref>
TISS LeapVault CLO Award, 2019<ref>{{Cite web|url=https://www.expresspharma.in/latest-updates/cadila-pharma-bags-tiss-leapvault-clo-awards-in-two-categories/|title=Cadila Pharma bags TISS LeapVault CLO awards in two categories|date=2019-08-09|website=Express Pharma|language=en-US|access-date=2019-10-16}}</ref>
 
Observenow Future of Workplace Award, 2019<ref>{{Cite web|url=http://thepharmatimes.in/cadila-pharma-wins-observenow-future-of-workplace-award/|title=Cadila Pharma wins ‘ObserveNow Future of Workplace Award’|last=Bureau|first=The Pharma Times News|date=2019-09-14|website=The Pharma Times {{!}} Pharma & Health Care News Portal|language=en-US|access-date=2019-10-16}}</ref>
 
Great Place to Work Certified, 2020<ref>{{Cite web|url=https://www.theweek.in/wire-updates/business/2020/03/06/pwr6-cadila%20pharmaceuticals.html|title=Cadila Pharmaceuticals Awarded Great Place To Work Certificate|website=The Week|language=en|access-date=2020-03-17}}</ref>


== References ==
== References ==
{{reflist}}
{{reflist}}


==External links==
* {{Official website|http://cadilapharma.com/}}
[[Category:Pharmaceutical industry in Gujarat]]
[[Category:Pharmaceutical industry in India| ]]
[[Category:Pharmaceutical companies of Gujarat]]
[[Category:Companies based in Ahmedabad]]
[[Category:Companies based in Ahmedabad]]
[[Category:Pharmaceutical companies established in 1951]]
[[Category:Pharmaceutical companies established in 1951]]

Latest revision as of 02:23, 14 October 2025



Cadila Pharmaceuticals Limited
IndustryPharmaceuticals
Founded1951
Founder(s)Indravadan Modi
Headquarters
Ahmedabad, Gujarat
,
India
Key people
Rajiv Modi
(Chairman and Managing Director)
ProductsAPIs, generic drugs
Services
RevenueIncrease ₹3,675 crore (US$520 million) (FY23)[1]
Decrease ₹−10 crore (US$−1.4 million) (FY23)[1]
Number of employees
8,000
SubsidiariesIRM Ltd
Websitewww.cadilapharma.com

Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.[2]

History[edit | edit source]

In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation.[3]

The Modi and Patel families decided to split the business in 1995, and two entities were formed: Cadila Pharmaceuticals Ltd (owned and controlled by Indravadan Modi and his son Rajiv Modi) and Cadila Healthcare (owned by Ramanbhai Patel and his son Pankaj Patel family).[3]

In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.[4]

In November 2023, the company opened an active pharmaceutical ingredient (API) plant in Dahej, in Gujarat's Bharuch district. The facility was built with an investment of ₹200 crore, and is equipped with distributed control system (DCS) automation technology. [5]

Operations[edit | edit source]

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.[6]

Controversies[edit | edit source]

Company[edit | edit source]

In 2014, a cautionary notice appeared on the US Food and Drug Administration (FDA) website, highlighting substantial manufacturing practice discrepancies discovered by inspectors in March at Cadila Pharmaceuticals' Ankleshwar facility in Gujarat.[7] This incident marked one among several Indian pharmaceutical companies receiving regulatory warnings from the FDA, indicating increased scrutiny on generic drugmakers.[8] A similar kind of notices were again issued in 2016[9] and 2019.[10]

Management[edit | edit source]

In 2018, the chairman of the company, Rajiv Modi, went through a widely publicized and contentious divorce with his wife, Monica, who comes from a prominent Mumbai-based business family of Garware. At that time, Modi transferred ₹200 crore (US$28 million) to Monica, who relinquished her rights, while custody of their son was awarded to Modi.[11][12]

References[edit | edit source]

  1. ↑ 1.0 1.1 "Cadila Pharmaceuticals Limited". Crediwatch. Retrieved 18 December 2023.
  2. ↑ "Cadila Pharma to expand and upgrade its existing facilities in Gujarat". BusinessLine. 22 March 2023. Retrieved 11 September 2023.
  3. ↑ 3.0 3.1 Das, Sohini (28 January 2014). "Carrying the legacy forward: Rajiv Modi" – via Business Standard.
  4. ↑ "Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients". @businessline. 10 January 2019. Retrieved 11 January 2019.
  5. ↑ "Business today". 27 November 2023.
  6. ↑ Financial Express 28 January 2013
  7. ↑ Mishra, Digbijay; Das, Sohini (13 November 2014). "US FDA scolds Cadila Pharma over manufacturing practice in Gujrat plant". Retrieved 6 January 2024.
  8. ↑ "FDA warns Cadila Pharma over drug production processes". Reuters. 12 November 2014. Retrieved 6 January 2023.
  9. ↑ RAJAGOPAL, DIVYA (1 January 2016). "Cadila gets US FDA warning for violating standards at Moraiya and Ahmedabad plants". The Economic Times. ISSN 0013-0389. Retrieved 6 January 2024.
  10. ↑ Research, Center for Drug Evaluation and (28 November 2022). "Cadila Healthcare Limited - 584856 - 10/29/2019". Center for Drug Evaluation and Research. Retrieved 6 January 2024.[dead link]
  11. ↑ "Gujarat: Cadila Pharma owner pays wife Rs 200 crore". The Times of India. 31 October 2018. ISSN 0971-8257. Retrieved 6 January 2024.
  12. ↑ "Cadila Pharmaceuticals boss Rajiv Modi swallows a Rs 200-cr divorce pill". DNA India. Retrieved 6 January 2024.

External links[edit | edit source]

Retrieved from "https://en.bharatpedia.org/w/index.php?title=Cadila_Pharmaceuticals&oldid=450584"
Discover more